Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F09%3A5805" target="_blank" >RIV/00216208:11110/09:5805 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/09:5805

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care

Original language description

Febrile neutropenia (FN) is a potentially life-threatening complication of myelosuppressive chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis if the overall FN risk to a patient is bigger or=20%, or if a reduction in chemotherapy dose intensity correlates with a poorer outcome.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical Drug Investigation

ISSN

1173-2563

e-ISSN

—

Volume of the periodical

2009

Issue of the periodical within the volume

29

Country of publishing house

NZ - NEW ZEALAND

Number of pages

23

Pages from-to

—

UT code for WoS article

000268545100001

EID of the result in the Scopus database

—